Proceeds to be utilized for general corporate purposes which may include the flexibility to invest in the growth of our ...

Moderna, Inc. MRNA stock is trading lower on Thursday after the company proposed a private placement of $2 billion of ...

The biotech firm announced plans to raise $2 billion through convertible notes, which could be increased to $2.3 billion.

By Mariam Sunny and Christy Santhosh Aug 25 (Reuters) - The personalized cancer vaccine being developed by Moderna and Merck ...

Moderna stock rallies as Wolfe Research upgrades it to "Peer Perform." But is there any further upside left in MRNA shares?

Prior to the melanoma outcome, indicators included an enrolled trial, a partner covering half the expenses, and a market that ...

Personalized mRNA shots may prove neither as wide-reaching nor as lucrative as hoped.

Moderna stock fell after announcing a $2 billion convertible notes plan to fund oncology growth, corporate needs, and debt ...

Dolly Parton‘s extraordinary legacy extended far beyond country music — with the late star even helping fund crucial research ...

Moderna and Merck's wild gambit on a cancer vaccine appears to have worked, despite big doubts, logistical challenges, and ...

Moderna stock is giving back a large chunk of Tuesday’s rally. The pullback reopens a question that a summer melt-up has ...

The combination regimen significantly extended the time patients lived without their melanoma returning, compared with ...